Estrogen Plus Progestin and Breast Cancer Incidence and Mortality in the Women’s Health Initiative Observational Study
2013; Oxford University Press; Volume: 105; Issue: 8 Linguagem: Inglês
10.1093/jnci/djt043
ISSN1460-2105
AutoresRowan T. Chlebowski, JoAnn E. Manson, Garnet L. Anderson, Jane A. Cauley, Aaron K. Aragaki, Marcia L. Stefanick, Dorothy S. Lane, Karen Johnson, Jean Wactawski‐Wende, Chu Chen, Lihong Qi, Shagufta Yasmeen, Polly A. Newcomb, Ross L. Prentice,
Tópico(s)Global Cancer Incidence and Screening
ResumoBackgroundIn the Women's Health Initiative (WHI) randomized trial, estrogen plus progestin increased both breast cancer incidence and mortality. In contrast, most observational studies associate estrogen plus progestin with favorable prognosis breast cancers. To address differences, a cohort of WHI observational study participants with characteristics similar to the WHI clinical trial was studied.
Referência(s)